Exploring the lutein therapeutic potential in steatotic liver disease: mechanistic insights and future directions
Frontiers in Pharmacology · 24.06.2024 · 15
DOI: 10.3389/fphar.2024.1406784 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.06.2024. Verfasst von Elisa Balboa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biomedical Research, Universidad Finis Terrae, Santiago, Chile. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The global prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is increasing, now affecting 25%–30% of the population worldwide. MASLD, characterized by hepatic steatosis, results from an imbalance in lipid metabolism, leading to oxidative stress, lipoperoxidation, and inflammation. The activation of autophagy, particularly lipophagy, alleviates hepatic steatosis by regulating intracellular lipid levels. Lutein, a carotenoid with antioxidant and anti-inflammatory properties, protects against liver damage, and individuals who consume high amounts of lutein have a lower risk of developing MASLD. Evidence suggests that lutein could modulate autophagy-related signaling pathways, such as the transcription factor EB (TFEB). TFEB plays a crucial role in regulating lipid homeostasis by linking autophagy to energy metabolism at the transcriptional level, making TFEB a potential target against MASLD. STARD3, a transmembrane protein that binds and transports cholesterol and sphingosine from lysosomes to the endoplasmic reticulum and mitochondria, has been shown to transport and bind lutein with high affinity. This protein may play a crucial role in the uptake and transport of lutein in the liver, contributing to the decrease in hepatic steatosis and the regulation of oxidative stress and inflammation. This review summarizes current knowledge on the role of lutein in lipophagy, the pathways it is involved in, its relationship with STARD3, and its potential as a pharmacological strategy to treat hepatic steatosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Biomedical Research, Universidad Finis Terrae, Santiago, Chile.
- Department of Gastroenterology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Zitieren
APA
Balboa, E., Saud, F., Parra-Ruiz, C., de la Fuente, M., Landskron, G., & Zanlungo, S. (2024). Exploring the lutein therapeutic potential in steatotic liver disease: mechanistic insights and future directions. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1406784
Vancouver
Balboa E, Saud F, Parra-Ruiz C, de la Fuente M, Landskron G, Zanlungo S. Exploring the lutein therapeutic potential in steatotic liver disease: mechanistic insights and future directions. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1406784
BibTeX
@article{Balboa2024,
author = {Balboa, Elisa and Saud, Faride and Parra-Ruiz, Claudia and de la Fuente, Marjorie and Landskron, Glauben and Zanlungo, Silvana},
title = {Exploring the lutein therapeutic potential in steatotic liver disease: mechanistic insights and future directions},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1406784}
}
EUVIMED